Motive Technologies, which develops and provides fleet management software and equipment, withdrew its plans for an initial public offering on Thursday. It originally filed in December 2025 for a deal we estimated could raise $600 million. The company had...read more
Updated Monday, 2/23. The typical February lull has taken hold of the IPO market while issuers work on year-end audited financials, but one sizable biotech is scheduled to go public before month end. Small deals may also join the calendar throughout the week. ...read more
Updated Monday, 1/5. One sizable deal is scheduled for the week ahead, with one smaller deal tentatively scheduled. Solid tumor biotech Aktis Oncology (AKTS) plans to raise $200 million at an $860 million market cap. The company is a Phase 1...read more
Fleet management software provider Motive Technologies withdraws IPO; takes growth financing from General Catalyst
Motive Technologies, which develops and provides fleet management software and equipment, withdrew its plans for an initial public offering on Thursday. It originally filed in December 2025 for a deal we estimated could raise $600 million. The company had...read more
US IPO Week Ahead: Asthma biotech set to close out February IPO market
Updated Monday, 2/23. The typical February lull has taken hold of the IPO market while issuers work on year-end audited financials, but one sizable biotech is scheduled to go public before month end. Small deals may also join the calendar throughout the week. ...read more
US IPO Week Ahead: Markets set for a quiet week after year’s first sizable IPO
...read more
US IPO Week Ahead: Aktis Oncology set to open 2026 IPO Market
Updated Monday, 1/5. One sizable deal is scheduled for the week ahead, with one smaller deal tentatively scheduled. Solid tumor biotech Aktis Oncology (AKTS) plans to raise $200 million at an $860 million market cap. The company is a Phase 1 ...read more